XOMA licenses technology to Diagnostic Products:
This article was originally published in Clinica
Executive Summary
XOMA has licensed to Diagnostic Products Corporation technology that uses lipopolysaccharide binding protein (LBP) technology which it will use to develop automated tests to detect systemic exposure to bacteria and endotoxin. Such conditions include sepsis and infectious complications of surgery and trauma. DPC has already developed automated tests for the early detection of sepsis and related infections. It claims the new technology may result in earlier diagnosis. XOMA has already licensed the LBP technology to Biosite Diagnostics to make and sell point-of-care diagnostics in the US and to SRL to make central lab tests in Japan.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.